What happened with MIRM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Mirum Pharmaceuticals sells Livmarli to relieve itching caused by impaired bile flow in patients with Alagille syndrome or progressive familial intrahepatic cholestasis. Its other approved medicines are Cholbam, for bile-acid synthesis disorders and certain peroxisomal disorders, and Ctexli, for adults with cerebrotendinous xanthomatosis. Product sales account for essentially all revenue.
Mirum markets Livmarli directly in the United States, Canada and certain European countries, and Cholbam and Ctexli directly in the United States. Licensing and distribution partners buy medicines for additional markets. In each of the United States and Canada, all sales of its approved medicines go through one specialty pharmacy. Patient access depends heavily on private insurers and government healthcare programs agreeing to cover treatment and reimburse its cost; continued demand also depends on patients benefiting and staying on treatment.
Mirum outsources manufacturing and depends on licensed rights to key medicines. Its Livmarli license requires royalties and milestone payments to Shire, and failure to meet license obligations can cost it commercialization rights. Approved drugs remain subject to safety and manufacturing requirements. Livmarli’s European authorization was granted under exceptional circumstances and undergoes annual review and renewal; medicines still in development cannot be marketed before regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Mirum’s results hinge on rare-liver-disease medicine sales and pipeline progress; watch Ipsen, absent from this list, whose odevixibat directly competes with Livmarli in ALGS and PFIC.
GSK’s linerixibat competes with Mirum’s volixibat to treat itching caused by impaired bile flow in patients with primary biliary cholangitis, with both targeting the IBAT pathway. Watch linerixibat’s regulatory progress: GSK reported that its Phase 3 trial met the primary itching endpoint and submitted marketing applications in the U.S., EU and other markets.
Vir Biotechnology’s tobevibart-elebsiran combination is in trials intended to support approval and targets the same chronic hepatitis D patients as Mirum’s brelovitug. Watch results from Vir’s ECLIPSE 1, 2 and 3 trials for evidence on this competing treatment.
Gilead Sciences already sells bulevirtide in the EU for chronic hepatitis D, competing in the market Mirum’s investigational brelovitug aims to enter. Watch Gilead’s bid for FDA approval to sell bulevirtide in the U.S., where Mirum reports no approved treatments for chronic hepatitis D.
Higher sales of Mirum’s acquired Chenodal and Cholbam bile-acid medicines can trigger payments to Travere Therapeutics, which sold the business to Mirum. Travere earned a $25 million sales milestone in 2025, making its milestone disclosures a concrete check on sales progress in this part of Mirum’s business.
GSK plc earningsGSK
GSK’s report will show how far its linerixibat for itching caused by primary biliary cholangitis has advanced toward market, where it would compete with Mirum’s volixibat for patients.
Watch linerixibat’s regulatory progress and whether its applications advance. If they do, patients with itching caused by impaired bile flow could have another treatment targeting the same IBAT pathway as Mirum’s volixibat, bringing competition closer; a setback would leave that path less advanced.
Gilead Sciences Inc earningsGILD
Gilead Sciences’ report will show how far its bulevirtide, already sold in the EU for chronic hepatitis D, is from the U.S. market that Mirum’s investigational brelovitug could also target.
Watch progress toward U.S. approval for bulevirtide. If it advances, Mirum’s brelovitug would face a competitor with existing EU sales experience if brelovitug reaches the U.S. chronic hepatitis D market; a delay would push that competitive prospect further out.
Travere Therapeutics, Inc. earningsTVTX
Travere Therapeutics’ report may show whether sales of the bile-acid medicines it sold to Mirum have triggered another milestone, revealing both sales progress and a payment obligation for Mirum.
Watch for Travere’s disclosure of another sales milestone. If one is triggered, sales of these bile-acid medicines have reached the agreed threshold, and Mirum owes a payment to Travere; no new milestone disclosed means there is no evidence of another triggered payment this period, not that the medicines had no sales.
Mirum Pharmaceuticals, Inc. earningsThis company
Mirum Pharmaceuticals’ report will show whether sales of Livmarli, Cholbam and Ctexli are growing enough to increasingly support its research and commercialization costs.
Read product sales alongside the operating loss. Rising sales with a narrower loss would show medicine revenue covering research and selling costs more effectively; slower sales or a wider loss would show that growth is not yet absorbing those costs. Large partner orders and updates to revenue estimates can make quarterly sales uneven, so a single quarter may not signal a change in demand.
